Nurix Therapeutics Valuation
| NRIX Stock | USD 19.14 0.35 1.80% |
At this time, the firm appears to be overvalued. Nurix Therapeutics secures a last-minute Real Value of $17.8 per share. The latest price of the firm is $19.14. Our model forecasts the value of Nurix Therapeutics from analyzing the firm fundamentals such as Shares Outstanding of 70.84 M, operating margin of (4.34) %, and Return On Equity of -0.58 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Nurix Therapeutics' valuation include:
Price Book 3.6635 | Enterprise Value | Enterprise Value Ebitda (3.35) | Price Sales 24.4683 | Enterprise Value Revenue 17.0085 |
Overvalued
Today
Please note that Nurix Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Nurix Therapeutics is based on 3 months time horizon. Increasing Nurix Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Nurix Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Nurix Stock. However, Nurix Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.14 | Real 17.8 | Target 31.94 | Hype 19.14 |
The intrinsic value of Nurix Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nurix Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Nurix Therapeutics helps investors to forecast how Nurix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nurix Therapeutics more accurately as focusing exclusively on Nurix Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Nurix Therapeutics' intrinsic value based on its ongoing forecasts of Nurix Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Nurix Therapeutics' closest peers.
Nurix Therapeutics Cash |
|
Nurix Valuation Trend
Analysing the historical paterns of Nurix Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Nurix Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Nurix Revenue by Product
Nurix Therapeutics Total Value Analysis
Nurix Therapeutics is now forecasted to have valuation of 959.69 M with market capitalization of 1.38 B, debt of 30.61 M, and cash on hands of 344.48 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Nurix Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
959.69 M | 1.38 B | 30.61 M | 344.48 M |
Nurix Therapeutics Investor Information
About 98.0% of the company shares are owned by institutional investors. The book value of Nurix Therapeutics was now reported as 5.62. The company recorded a loss per share of 2.85. Nurix Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Nurix Therapeutics' liquidity, profitability, solvency, and operating efficiency, Nurix Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.Nurix Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Nurix Therapeutics has an asset utilization ratio of 21.65 percent. This suggests that the Company is making $0.22 for each dollar of assets. An increasing asset utilization means that Nurix Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Nurix Therapeutics Ownership Allocation
Nurix Therapeutics maintains a total of 70.84 Million outstanding shares. The majority of Nurix Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Nurix Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Nurix Therapeutics. Please pay attention to any change in the institutional holdings of Nurix Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Nurix Therapeutics Profitability Analysis
The company reported the previous year's revenue of 76.99 M. Net Loss for the year was (143.95 M) with loss before overhead, payroll, taxes, and interest of (147.7 M).About Nurix Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Nurix Therapeutics. We calculate exposure to Nurix Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Nurix Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -100.9 M | -95.9 M | |
| Pretax Profit Margin | (2.15) | (2.26) | |
| Operating Profit Margin | (2.32) | (2.43) | |
| Net Loss | (2.15) | (2.26) | |
| Gross Profit Margin | (1.31) | (1.25) |
Nurix Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 54.3 M |
Nurix Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Nurix Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Nurix we look at many different elements of the entity such as Nurix's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Nurix Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Nurix Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Nurix Therapeutics' worth.Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.